Chemo Iberica
Chemo Iberica, part of Spain's Insud Pharma group, manufactures Active Pharmaceutical Ingredients and Finished Dosage Forms. It provides end-to-end CDMO/CMO services spanning R&D through commercialization to pharmaceutical companies across 50+ countries for human and animal health.
- Company typePrivate
- Founded1940
- HeadquartersMadrid, Spain
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Chemo Iberica does
Chemo Iberica, S.A. is a Spain-headquartered pharmaceutical manufacturer operating as a core business unit within the Insud Pharma group. The company specializes in the production of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs), serving pharmaceutical companies globally across more than 50 countries. It also operates in the agrochemicals and crop protection sector under its predecessor identity Chemotecnica SA. Originally founded in 1940, Chemo was rebranded in 2020 as part of its formal integration into the Insud Pharma corporate platform, which unifies multiple pharmaceutical subsidiaries under one corporate identity.
The company's technical capabilities center on end-to-end pharmaceutical manufacturing infrastructure, with 21 industrial manufacturing plants and 15 R&D centers deployed globally under the Insud Pharma umbrella. Its technology stack spans the full pharmaceutical value chain — from active ingredient synthesis through finished dosage form production — supported by a workforce of more than 10,000 professionals across the parent group. The platform architecture extends to adjacent biotech capabilities via sister subsidiaries, including monoclonal antibody production (mAbxience), algae-based pharmaceutical solutions (Algenex), and bionanopharmaceutical drug delivery (Bionanopharma). Additional platform elements include the ChemoStart innovation and startup support program, and Insud Power, a renewable energy subsidiary serving the group's industrial operations.
Chemo's commercial model is bifurcated. The primary revenue stream is contract development and manufacturing (CDMO/CMO) services delivered to enterprise pharmaceutical clients, where the company acts as an outsourced manufacturing partner for APIs and FDFs. A secondary stream is the commercialization of proprietary brand medications for human and animal health, leveraging Insud Pharma's commercial distribution infrastructure. The company serves B2B pharmaceutical customers through direct field sales and enterprise relationships, with pricing conducted via quote-based contracts rather than public disclosure. Marketing and lead generation rely on industry pharmaceutical conferences and exhibitions, along with the Insud Pharma corporate website and brand portfolio targeting enterprise pharmaceutical buyers across global markets.
Chemo Iberica firmographics
Firmographics- Name
- Chemo Iberica
- Legal name
- Chemo Iberica
- Website
- https://chemogroup.com
- Company type
- Private
- Founded year
- 1940
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Chemo Iberica, part of Spain's Insud Pharma group, manufactures Active Pharmaceutical Ingredients and Finished Dosage Forms. It provides end-to-end CDMO/CMO services spanning R&D through commercialization to pharmaceutical companies across 50+ countries for human and animal health.
- Ownership category
- akta.pro rank
Chemo Iberica industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
Keywords
Where Chemo Iberica is headquartered
LocationHeadquarters
- HQ city
- Madrid
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
Chemo Iberica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- CDMO/CMO Pharmaceutical Services: Contract development and manufacturing services for pharmaceutical companies, offering end-to-end services from R&D to manufacturing and commercialization of APIs and Finished Dosage Forms for human and animal health.
- Brand Medications: Commercialization of proprietary brand medications for human and animal health through the Insud Pharma group's commercial infrastructure.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Chemo Iberica product offering
Product offeringCore offering
Chemo Iberica, S.A. manufactures and distributes generic medicines and pharmaceutical products as part of the Insud Pharma group. The company produces Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) for both human and animal health markets, and offers contract development and manufacturing (CDMO/CMO) services to global pharmaceutical companies alongside the commercialization of brand medications.
Product overview
Insud Pharma operates as a unified pharmaceutical platform with multiple subsidiaries and brands. The parent company provides end-to-end CDMO (Contract Development and Manufacturing Organization) and CMO (Contract Manufacturing Organization) services, covering the entire value chain from R&D to manufacturing and commercialization of APIs (Active Pharmaceutical Ingredients), FDFs (Finished Dosage Forms), and branded medicines for human and animal health. The portfolio includes specialized subsidiaries: Chemo (API manufacturing), Exeltis (specialty pharmaceuticals), mAbxience (monoclonal antibodies/biotech), Algenex (alga-based biotech), and Bionanopharma (bionanopharmaceuticals). Additional services include ChemoStart (innovation program) and Insud Power (renewable energy).
Differentiator
Problem solved
Functional benefit
Brands
- Chemo: Pharmaceutical brand under Insud Pharma group specializing in APIs and pharmaceutical manufacturing
Products and services
- Active Pharmaceutical Ingredients (APIs) Manufacture of Active Pharmaceutical Ingredients supplied to pharmaceutical companies for use in human and animal health drug formulations.
- Finished Dosage Forms (FDFs) Contract manufacturing of finished dosage forms (tablets, capsules and other dose forms) for human and animal health markets, supplied to pharmaceutical companies.
- Brand Medications (Human Health) Commercialization of branded pharmaceutical products for the human health market, distributed through the Insud Pharma group's commercial channels.
- Brand Medications (Animal Health) Commercialization of branded pharmaceutical products for the animal health market, distributed through the Insud Pharma group's commercial channels.
- CDMO/CMO Pharmaceutical Services Contract development and contract manufacturing services for global pharmaceutical companies, covering APIs, finished dosage forms, and formulation development across the Insud Pharma group's 21 manufacturing plants and 15 R&D centers.
Companies that use Chemo Iberica
Customer profileSegments2 records
Ideal customer profiles1 record
Chemo Iberica technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Chemo Iberica partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Insud PharmaparentChemo operates as a business unit/brand within the Insud Pharma group. Insud Pharma is a global pharmaceutical group offering end-to-end CDMO and CMO services, operating from R&D through manufacturing and commercialization of APIs, FDFs, and brand medications for human and animal health. The group includes subsidiaries Chemo, Exeltis, Mabxience, Algenex, and Bionanopharma.
Scale indicators5 records
Recent moves5 records
Expansion highlights5 records
Chemo Iberica competitors and assessment
Company assessmentDirect peers
- Laboratorios Farmaceuticos Rovi: Spanish pharmaceutical company with own-brand generics, CDMO services, and APIs; comparable to Chemo in vertically integrated pharma manufacturing from a similar Madrid/Spain base.
- Hovione: Portugal-based CDMO specializing in APIs and drug product services for global pharma; comparable to Chemo in offering integrated contract development and manufacturing for both drug substance and drug product.
- Laboratorios Normon: Spanish generic pharmaceutical manufacturer with broad API and FDF capabilities, directly comparable to Chemo's generic pharma manufacturing and CDMO services from a similar Iberian base.
- Recipharm: European CDMO offering contract development and manufacturing of pharmaceuticals across multiple dosage forms; directly comparable to Chemo's CDMO/CMO business in APIs and FDFs.
- Uquifa: Spain- and Mexico-based API manufacturer serving global generics and animal health markets; comparable to Chemo's API manufacturing and veterinary pharma exposure.
Broad incumbents
- Lonza Group: One of the world's largest CDMOs across small molecules, biologics, and cell & gene therapy; competes with Chemo for outsourced pharma manufacturing, particularly through scale and modality breadth.
- Aurobindo Pharma: Large global generics and API manufacturer with significant CDMO operations; a broader incumbent that competes with Chemo in generic APIs and contract manufacturing for human and animal health.
- Catalent: Major global CDMO offering drug substance, drug product, and biologic services; overlaps with Chemo's integrated CDMO offering and competes for large pharma outsourcing contracts.
- Sandoz (Novartis): Global generics leader with in-house API manufacturing and growing CDMO services; directly comparable to Chemo's generics focus and integrated API plus FDF model.
Emerging players
- mAbxience (Insud Pharma subsidiary): CDMO and biosimilars developer focused on monoclonal antibodies, operating within the same parent group as Chemo; relevant peer for biologics CDMO capabilities being developed by Insud Pharma.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Chemo Iberica social profiles
Digital presenceChemo Iberica financial estimates
Financial estimateRevenue estimate
Valuation estimate
Chemo Iberica leadership team
Management profileNumber of profiles
Profiles1 record
Chemo Iberica funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Chemo Iberica M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Chemo Iberica
What does Chemo Iberica do?
Chemo Iberica, S.A. manufactures and distributes generic medicines and pharmaceutical products as part of the Insud Pharma group. The company produces Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) for both human and animal health markets, and offers contract development and manufacturing (CDMO/CMO) services to global pharmaceutical companies alongside the commercialization of brand medications.
Is Chemo Iberica a public or private company?
Chemo Iberica is a private company. It is classified as corporate owned and is currently operating.
When was Chemo Iberica founded?
Chemo Iberica was founded in 1940. It employs 5,001 to 10,000 people.
Where is Chemo Iberica based?
Chemo Iberica is headquartered in Madrid, Spain, in the Europe region.
How does Chemo Iberica make money?
Two revenue lines are on record. CDMO/CMO Pharmaceutical Services are the primary driver. The others are brand Medications.
Who are Chemo Iberica's main competitors?
Direct peers on record are Laboratorios Farmaceuticos Rovi, Hovione, Laboratorios Normon, Recipharm and Uquifa. Broad incumbents are Lonza Group, Aurobindo Pharma, Catalent and Sandoz (Novartis). mAbxience (Insud Pharma subsidiary) is listed as an emerging player.
Does Chemo Iberica have an API?
No public API is recorded for Chemo Iberica.
What industry is Chemo Iberica in?
Chemo Iberica's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 325412 and its SIC code is 2834.